Washington, D.C., USA - December 22, 2010, Washington, D.C., USA - The Pharmaceutical Research and Manufacturers of America (PhRMA) announced the election of Ian Read, Jerzy Gruhn, Mark Iwicki and Staffan Schüberg to its board of directors.
Article continues below
r>
Ian Read was recently named President and Chief Executive Officer of Pfizer Inc. Previously. Previously, he served as Senior Vice President, Pfizer Inc, and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units — Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.
Mr. Read began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions in a number of Pfizer's largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil.
In 1996, he was appointed President of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.
Mr. Read received his B.Sc. in chemical engineering from London University Imperial College in 1974. He earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales in 1978. He serves on the Board of Kimberly-Clark as well as on the U.S. Council for International Business and the European Federation of Pharmaceutical Industries and Associations.
Jerzy Gruhn serves as President of Novo Nordisk, Inc. and Senior Vice President of Novo Nordisk North America, having joined the U.S. business in 2008. Mr. Gruhn has worked in the biopharmaceutical sector for more than 20 years. During his 11 years with Novo Nordisk, Mr. Gruhn has played a critical role in the company’s growth in Central and Eastern Europe, positively transforming that region’s business performance.
As a person with diabetes, Mr. Gruhn has made it his personal and professional mission to help advance diabetes care through awareness, prevention, education and policy changes. In 2003, Mr. Gruhn was awarded the Silver Cross of Merit by the President of Poland for his involvement in the improvement of diabetes care in the country.
Mark Iwicki was elevated to the position of President and Chief Operating Officer of Sepracor – now Sunovion Pharmaceuticals Inc. – in February 2010. While in this position, he was responsible for shepherding Sepracor through the company’s acquisition by Dainippon Sumitomo Pharma Co., Ltd., now Sunovion’s Japanese parent, and the merger with DSP’s U.S. subsidiary, Dainippn Sumitomo Pharma America.
Prior to this position, Mr. Iwicki served as Executive Vice President and Chief Commercial Officer for three years. Before joining Sunovion Pharmaceuticals Inc., Mr. Iwicki held several senior positions at Novartis Pharmaceuticals from 1998 through 2007. He has also worked in various positions at Merck and Astra Merck.
Staffan Schüberg assumed the role of President, Lundbeck Inc., in November 2010. Mr. Schüberg has held various positions within Lundbeck over the course of several years. He began his career with H. Lundbeck A/S in 1994, serving in a product management role in South Africa before becoming a central nervous system product manager in Sweden. ■